ClinicalTrials.gg
RecruitingNCT07339709IPPUpdated Jan 14, 2026

Intraperitoneal Pressure Measurements Survey in Pediatric Centers

An observational study in Pediatric Renal Failure, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.

Planned enrollment
27th of 40
100 · median 177
Started
2025
with 3 others
Observational
40 of 145
10 open now
Primary completion
2026-07
later than 8 of 32 live
Registered
143rd of 145
by date
Lead sponsor
4 of 145
University Hospital, Strasbourg, France

Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 27th largest by planned enrollment of the 40 observational ones that give a count, is one of 4 that started in 2025, is one of 40 observational ones, reaches primary completion later than 8 of the 32 other live ones, and was the 143rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Kidney Failure, Chronic with a site in France, or all of them as a file.
02

Study summary

Intraperitoneal pressure (IPP) is an objective measurement used to assess tolerance to fluid volume. IPP has been shown to be strongly correlated with intraperitoneal dialysate volume as well as anthropometric parameters. In observational studies conducted in adults, an IPP greater than 13-14 cmH2O was associated with an increased risk of peritonitis, initiation of hemodialysis, or death.

Measuring IPP is therefore a tool to optimize dialysis prescriptions. However, this measurement is not well standardized, and there is limited scientific evidence regarding its impact on patient management.

Measuring IPP is a tool to optimize dialysis prescriptions. However, this measurement is not well standardized, and there is limited scientific evidence regarding its impact on patient management. Some centers do not perform any measurements, others perform them monthly, and some only during peritoneal equilibration tests.

The hypothesis of this research is to highlight current practices and experiences in measuring intraperitoneal pressures in children undergoing peritoneal dialysis in different European dialysis centers, in order to improve practices regarding PIP prescription.

03

Conditions studied

  • Pediatric Renal Failure

Keywords

  • Pediatric Renal Failure
  • Peritoneal dialysis
  • Intraperitoneal pressure
  • Intraperitoneal dialysates
  • End-stage renal disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Healthcare professional working in a European dialysis center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Healthcare professional working in a European dialysis center

Exclusion criteria

Exclusion Criteria:

- Refusal to participate in the study.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Review of current practices in measuring intraperitoneal pressures in children undergoing peritoneal dialysis

    This study aims to provide an overview of current experiences in measuring intraperitoneal pressures in children undergoing peritoneal dialysis in different European dialysis centers.

    Time frame: Up to 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2026, 12 months after the start.

Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 12 months is below that.

Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 14, 2026
StartActual
Jul 16, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Jul 16, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07339709
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Jul 16, 2025
Primary completion
Jul 2026 (estimated)
Completion
Jul 16, 2026 (estimated)
Last update
Jan 14, 2026

Study contacts

Ariane ZALOSZYC, MD, PhD
Contact
ariane.zaloszyc@chru-strasbourg.fr
33 3 88 12 77 42

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion